These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34027890)

  • 1. Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample.
    Palamar JJ
    Am J Prev Med; 2021 Aug; 61(2):240-245. PubMed ID: 34027890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kratom Use Among U.S. Adolescents: Analyses of the 2019 National Survey on Drug Use and Health.
    Sharma V; Cottler LB; Bares CB; Lopez-Quintero C
    J Adolesc Health; 2022 Apr; 70(4):677-681. PubMed ID: 34836801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.
    Garcia-Romeu A; Cox DJ; Smith KE; Dunn KE; Griffiths RR
    Drug Alcohol Depend; 2020 Mar; 208():107849. PubMed ID: 32029298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Illicitly Manufactured Fentanyl Use Among Individuals in the U.S., 2022.
    Palamar JJ
    Am J Prev Med; 2024 Aug; 67(2):285-290. PubMed ID: 38527696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study.
    Schimmel J; Amioka E; Rockhill K; Haynes CM; Black JC; Dart RC; Iwanicki JL
    Addiction; 2021 Jan; 116(1):176-181. PubMed ID: 32285981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
    Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
    J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.
    Smith KE; Rogers JM; Strickland JC
    J Psychoactive Drugs; 2022; 54(5):429-439. PubMed ID: 34842079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual Orientation Disparities in Prescription Opioid Misuse Among U.S. Adults.
    Duncan DT; Zweig S; Hambrick HR; Palamar JJ
    Am J Prev Med; 2019 Jan; 56(1):17-26. PubMed ID: 30467089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users.
    Smith KE; Bunting AM; Walker R; Hall MT; Grundmann O; Castillo O
    J Psychoactive Drugs; 2019; 51(4):311-322. PubMed ID: 30961450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and characteristics of self-reported kratom use in a representative US general population sample.
    Covvey JR; Vogel SM; Peckham AM; Evoy KE
    J Addict Dis; 2020; 38(4):506-513. PubMed ID: 32657217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kratom (Mitragyna speciosa): A Case Review of Use Before and During Pregnancy.
    Faucher MA; Morillos S; Cordova P; McNeil-Santiel J; Onisko N; Adhikari EH; Nelson DB
    J Midwifery Womens Health; 2024; 69(1):144-149. PubMed ID: 37679866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabis and Prescription Drug Use Among Older Adults With Functional Impairment.
    Han BH; Le A; Funk-White M; Palamar JJ
    Am J Prev Med; 2021 Aug; 61(2):246-250. PubMed ID: 34288869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmedical Use of Prescription Opioids among Pregnant U.S. Women.
    Kozhimannil KB; Graves AJ; Levy R; Patrick SW
    Womens Health Issues; 2017; 27(3):308-315. PubMed ID: 28408072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
    Hong S; Zimmerman PE; Rao V; Markwalter DW
    J Palliat Med; 2023 May; 26(5):734-736. PubMed ID: 36580544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kratom (Mitragyna speciosa): worldwide issues.
    Ramanathan S; McCurdy CR
    Curr Opin Psychiatry; 2020 Jul; 33(4):312-318. PubMed ID: 32452943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marijuana users are likely to report opioid misuse among adults over 50 years in representative sample of the United States (2002-2014).
    Ramadan MM; Banta JE; Bahjri K; Montgomery SB
    J Addict Dis; 2021; 39(1):66-73. PubMed ID: 32935646
    [No Abstract]   [Full Text] [Related]  

  • 18. Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.
    Smith KE; Dunn KE; Grundmann O; Garcia-Romeu A; Rogers JM; Swogger MT; Epstein DH
    Exp Clin Psychopharmacol; 2022 Dec; 30(6):983-996. PubMed ID: 34735202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between E-cigarette use and Kratom use among US adults.
    Lee J; Terashima JP; Parker MA
    Prev Med; 2022 Nov; 164():107295. PubMed ID: 36208816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample.
    Mannes ZL; Livne O; Knox J; Hasin DS; Kranzler HR
    Am J Drug Alcohol Abuse; 2023 Nov; 49(6):799-808. PubMed ID: 37948571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.